Systemic mastocytosis: Bone marrow pathology, classification, and current therapies

Medicine & Life Sciences

• Systemic Mastocytosis 100%
• Mastocytosis 95%
• Bone Marrow 49%
• Mast Cells 44%
• Pathology 43%
• Tryptases 29%
• Eosinophilia 24%
• Pdgfra-Associated Chronic Eosinophilic Leukemia 19%
• Bone Marrow Examination 15%
• Platelet-Derived Growth Factor Receptors 15%
• Imatinib Mesylate 12%
• Hematologic Neoplasms 11%
• Therapeutics 11%
• Oncogenes 10%
• Cell- and Tissue-Based Therapy 10%
• Interferons 10%
• Coloring Agents 9%
• Drug Therapy 6%
• Mutation 6%
• Growth 5%
• Serum 5%